At the end of November 2019, the report of the project OTCA17, titled “Lithium triborate (LBO) laser for photoselective vaporization of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)” was published on the website of the European Network for HTA (EUnetHTA).

On October 29, 2019, the NHS England updated the clinical commissioning work programs including clinical commissioning policy work program, specialized commissioning service specification work program, commissioning through evaluation work programs.

The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in November 2019 concern various types of devices, including orthopaedic, and cardiovascular devices. A total of twenty-four decisions were made.

In November 2019, the Skåne Region released an HTA report for arthroscopic subacromial decompression (ASD) in subacromial pain syndrome that aimed to evaluate the scientific evidence for the procedure. It was concluded that the degree of clinical evidence is limited due to lack of study quality; the certain safety conclusions cannot be drawn due to the data diversity.

With the support of Aaron.ai, the first health application from the project “KBV Future Practice” ("KBV-Zukunftspraxis") was launched in Germany. About 50 medical practices are now testing the smart telephone assistant in their daily work. The evaluation of the practical tests is carried out by the Charité.

In October 2019, the Agency for Health Quality and Assessment of Catalonia (AQuAS) has released an assessment report regarding the evaluation strategies to prevent urinary tract infections associated with urethral/urinary catheters in critical patients in Intensive Care Units. The evidence is not conclusive, but there is scientific evidence that aims for the introduction of review measures for the indication of indwelling urethral/urinary catheters, its use in decubitus, and without kinking.

The Clinical Coding and Schedule Development (CCSD) group develops and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern injection eustachian tuboplasty, extracorporeal shockwave therapy for carpal tunnel syndrome, robotic-assisted laparoscopic excision of recto-vaginal endometriosis, and diagnostic codes for alpha-melanocyte stimulating hormone, NK cell inhibition panel, XR whole spine, and others. The codes are introduced with a recommended adoption date being the 1st of February 2020. The documents also contain a list of textual changes in codes, unacceptable combinations, and inactivated codes.

Since autumn 2019, MTRC started the release of the Market Access Magazine with an overview of key reimbursement news for the last quarter, along with analytical reviews on the topic of market access for medical technologies (reimbursement, funding, HTA, innovation payment schemes). Download free of charge from our website.

In Sweden, the Centre for Assessment of Medical Technology (CAMTÖ) leads the development of HTA cooperation in the healthcare region Uppsala-Örebro. In September 2019, CAMTÖ released an HTA report on PD-L1 positivity tested by McAb SP263 to guide immune checkpoint therapy in non-small-cell lung cancer. No safe conclusions could be drawn, but the wide range of positivity rates implies the difficulties in the standardization of PD-L1 expression and the need for better predictive biomarkers.

In late October 2019, the DIMDI (German Institute of Medical Documentation and Information) has published the final version of the OPS 2020 (Operation and Procedure Keys). The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification) forms the basis for the reimbursement systems in outpatient and inpatient care.

In November 2019, the two new mini-method assessments for ankyloglossia and rapid testing for chlamydia and gonorrhea were initiated by Oslo University. After the completion of the assessment procedure, the final reports would be available via a mini-HTA database.

In October 2019, the Agency for Health Quality and Assessment of Catalonia (AQuAS) has released an assessment report regarding the scientific evidence on personalized population screening for breast cancer. The current evidence does not allow to recommend any concrete models for individualized risk prediction for breast cancer but allows to recommend the development and evaluation of new models for personalized risk prediction directed to offering different strategies to the screening of population.